Clinical benefit from ipilimumab therapy in melanoma patients may be associated with serum CTLA4 levels

Frontiers in Oncology

Volumn 4 MAY, Issue , 2014, Pages

  Leung M , Anna ^a   Lee, Agnes Fermin ^a   Ozao Choy, Junko ^a   Ramos, Romela Irene ^a   Hamid, Omid ^b   O'Day, Steven J ^c   Shin Sim, Myung ^a   Morton L , Donald ^a   Faries B , Mark ^a   Sieling A , Peter ^a   Lee, Delphine J ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b Angeles Clinic and Research Institute   (United States)

^c Beverly Hills Cancer Center   (United States)

Author keywords

Clinical benefit; Ipilimumab; Metastatic melanoma; Response to therapy; Serum; Soluble CTLA4; Survival

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; IPILIMUMAB;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MALE; MELANOMA; OVERALL SURVIVAL; PREDICTIVE VALUE; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE;

EID: 84904627751     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00110     Document Type: Article

References (27)

1. Leung AM, Hari DM, Morton DL. Surgery for distant melanoma metastasis. Cancer J (2012) 18:176-84. doi: 10.1097/PPO.0b013e31824bc981
2. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363:711-23. doi:10.1056/NEJMoa1003466
3. Magistrelli G, Jeannin P, Herbault N, Benoit De Coignac A, Gauchat JF, Bonnefoy JY, et al. A soluble form of CTLA-4 generated by alternative splicing is expressed by nonstimulated human T cells. Eur J Immunol (1999) 29:3596-602. doi:10.1002/(SICI)1521-4141(199911)29:11<3596::AID-IMMU3596>3.0.CO;2-Y
4. Linsley PS, Bradshaw J, Greene J, Peach R, Bennett KL, Mittler RS. Intracellular trafficking of CTLA-4 and focal localization towards sites of TCR engagement. Immunity (1996) 4:535-43. doi:10.1016/S1074-7613(00)80480-X
5. Wang XB, Zheng CY, Giscombe R, Lefvert AK. Regulation of surface and intracellular expression of CTLA-4 on human peripheral T cells. Scand J Immunol (2001) 54:453-8. doi:10.1046/j.1365-3083.2001.00985.x
6. Jago CB, Yates J, Camara NO, Lechler RI, Lombardi G. Differential expression of CTLA-4 among T cell subsets. Clin Exp Immunol (2004) 136:463-71. doi:10.1111/j.1365-2249.2004.02478.x
7. Brunet JF, Denizot F, Luciani MF, Roux-Dosseto M, Suzan M, Mattei MG, et al. A new member of the immunoglobulin superfamily - CTLA-4. Nature (1987) 328:267-70. doi:10.1038/328267a0
8. Walunas TL, Bakker CY, Bluestone JA. CTLA-4 ligation blocks CD28-dependent T cell activation. J Exp Med (1996) 183:2541-50. doi:10.1084/jem.183.6.2541
9. O'Day SJ, Hamid O, Urba WJ. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer (2007) 110:2614-27. doi:10.1002/cncr.23086
10. Tivol EA, Borriello F, Schweitzer AN, Lynch WP, Bluestone JA, Sharpe AH. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity (1995) 3:541-7. doi:10.1016/1074-7613(95)90125-6
11. Oaks MK, Hallett KM, Penwell RT, Stauber EC, Warren SJ, Tector AJ. A native soluble form of CTLA-4. Cell Immunol (2000) 201:144-53. doi:10.1006/cimm.2000.1649
12. Ward FJ, Dahal LN, Wijesekera SK, Abdul-Jawad SK, Kaewarpai T, Xu H, et al. The soluble isoform of CTLA-4 as a regulator of T-cell responses. Eur J Immunol (2013) 43:1274-85. doi:10.1002/eji.201242529
13. Nagasawa M, Zhu Y, Isoda T, Tomizawa D, Itoh S, Kajiwara M, et al. Analysis of serum soluble CD40 ligand (sCD40L) in the patients undergoing allogeneic stem cell transplantation: platelet is a major source of serum sCD40L. Eur J Haematol (2005) 74:54-60. doi:10.1111/j.1600-0609.2004.00342.x
14. Erfani N, Razmkhah M, Ghaderi A. Circulating soluble CTLA4 (sCTLA4) is elevated in patients with breast cancer. Cancer Invest (2010) 28:828-32. doi:10.3109/07357901003630934
15. Simone R, Pesce G, Antola P, Rumbullaku M, Bagnasco M, Bizzaro N, et al. The soluble form of CTLA-4 from serum of patients with autoimmune diseases regulates T-cell responses. Biomed Res Int (2014) 2014:9. doi:10.1155/2014/215763
16. Linsley PS, Greene JL, Tan P, Bradshaw J, Ledbetter JA, Anasetti C, et al. Coexpression and functional cooperation of CTLA-4 and CD28 on activated T lymphocytes. J Exp Med (1992) 176:1595-604. doi:10.1084/jem.176.6.1595
17. Grohmann U, Orabona C, Fallarino F, Vacca C, Calcinaro F, Falorni A, et al. CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat Immunol (2002) 3:1097-101. doi:10.1038/ni846
18. Dejean AS, Beisner DR, Ch'en IL, Kerdiles YM, Babour A, Arden KC, et al. Transcription factor Foxo3 controls the magnitude of T cell immune responses by modulating the function of dendritic cells. Nat Immunol (2009) 10:504-13. doi:10.1038/ni.1729
19. Ozao-Choy J, Carvajal RD, Hamid O. Ipilimumab for metastatic melanoma. Drugs Today (Barc) (2012) 48:381-93.
20. Robert C, Thomas L, Bondarenko I, O'Day S, JW MD, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364:2517-26. doi:10.1056/NEJMoa1104621
21. Garbe C, Peris K, Hauschild A, Saiag P, Middleton M, Spatz A, et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - update 2012. Eur J Cancer (2012) 48:2375-90. doi:10.1016/j.ejca.2012.06.013
22. Spagnolo F, Queirolo P. Upcoming strategies for the treatment of metastatic melanoma. Arch Dermatol Res (2012) 304:177-84. doi:10.1007/s00403-012-1223-7
23. Erfani N, Mehrabadi SM, Ghayumi MA, Haghshenas MR, Mojtahedi Z, Ghaderi A, et al. Increase of regulatory T cells in metastatic stage and CTLA-4 over expression in lymphocytes of patients with non-small cell lung cancer (NSCLC). Lung Cancer (2012) 77:306-11. doi:10.1016/j.lungcan.2012.04.011
24. Santegoets SJ, Stam AG, Lougheed SM, Gall H, Scholten PE, Reijm M, et al. T cell profiling reveals high CD4+CTLA-4 + T cell frequency as dominant predictor for survival after prostate GVAX/ipilimumab treatment. Cancer Immunol Immunother (2013) 62:245-56. doi:10.1007/s00262-012-1330-5
25. Hamid O, Schmidt H, Nissan A, Ridolfi L, Aamdal S, Hansson J, et al. A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. J Transl Med (2011) 9:204. doi:10.1186/1479-5876-9-204
26. Yuan J, Adamow M, Ginsberg BA, Rasalan TS, Ritter E, Gallardo HF, et al. Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab. Proc Natl Acad Sci U S A (2011) 108:16723-8. doi:10.1073/pnas.1110814108
27. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, et al. Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer (2010) 116:1767-75. doi:10.1002/cncr.24951